Cargando…
Pharmacokinetics of Octreotide in Patients With Cirrhosis and Portal Hypertension; Relationship Between the Plasma Levels of the Analogue and the Magnitude and Duration of the Reduction in Corrected Wedged Hepatic Venous Pressure
In healthy subjects octreotide is largely metabolised by the liver suggesting that the plasma half-life of the somatostatin analogue may be prolonged in patients with hepatic dysfunction. The aim of this study was therefore (a) to determine the pharmacokinetics of octreotide following its subcutaneo...
Autores principales: | Jenkins, S. A., Nott, D. M., Baxter, J. N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423925/ https://www.ncbi.nlm.nih.gov/pubmed/9830576 http://dx.doi.org/10.1155/1998/17436 |
Ejemplares similares
-
The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
por: Mejias, Marc, et al.
Publicado: (2008) -
Relationship between hemodynamic parameters and portal venous pressure in cirrhosis patients with portal hypertension
por: Yao, Hongjuan, et al.
Publicado: (2020) -
Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide
por: Patel, Sharad, et al.
Publicado: (2017) -
The Duration and Magnitude of Postdischarge Venous Thromboembolism Following Colectomy
por: Lewis-Lloyd, Christopher A., et al.
Publicado: (2022) -
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
por: Cui, Pei-Jing, et al.
Publicado: (2017)